Table 2.
Factors affecting engraftment rates in recurrent EOC-PDX models.
| Factors | N | Success | Failure | p-value | |
|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | ||||
| Age (years) | 21 | 52.87 ± 9.59 | 59.5 ± 6.55 | 0.115 | 0.187 |
| Types of recurrence | 1.00 | ||||
| Platinum sensitive | 13 | 9 | 4 | ||
| Platinum resistance | 8 | 6 | 2 | ||
| CA125 (U/ml) | 21 | 90.5 | 115.3 | 0.448 | |
| (35.45, 630.8) | (81.23, 221.6) | ||||
| Pathological type | 0.526 | ||||
| Type I EOC | 3 | 3 | 0 | ||
| Type II EOC | 18 | 12 | 6 | ||
| Cancer grade | 1.00 | ||||
| Low–intermediate | 1 | 1 | 0 | ||
| High | 20 | 14 | 6 | ||
| FIGO stage | 0.327 | ||||
| II | 1 | 1 | 0 | ||
| III | 17 | 11 | 6 | ||
| IV | 3 | 3 | 0 | ||
| Ki-67(positive%) | 21 | 60% | 40% | 0.445 | |
| (40%, 75%) | (28.75%, 70%) | ||||
| TP53 | 0.079 | 0.999 | |||
| Wild type | 2 | 0 | 2 | ||
| Mutant type | 18 | 14 | 4 | ||
| BRCA1/2 | 1.00 | ||||
| Wild type | 4 | 3 | 1 | ||
| Mutant type | 4 | 3 | 1 | ||
Age is described as mean ± SD, and CA125 and Ki-67 level are described as median (quartiles).
EOC, epithelial ovarian cancer; PDX, patient-derived xenograft; NACT, neoadjuvant chemotherapy; FIGO, International Federation of Gynecology and Obstetrics.